
BeiGene’s Tevimbra combination granted EC approval in small cell lung cancer
BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a first-line combination treatment for an aggressive form of lung cancer. The drug has been specifically authorised in combination with …